Abstract
Atrial fibrillation (AF) is a frequent and costly health care problem and represents the most common arrhythmia resulting in hospital admission. The overall prevalence of AF in the United States ranges from <1% in young, otherwise healthy individuals up to nearly 9% in elderly patients. AF may cause disabling symptoms and serious adverse effects such as impairment of cardiac function or thromboembolic events. Due to the limited efficacy of antiarrhythmic drugs for AF, several non-pharmacologic options have evolved including pacemaker therapy, transvenous catheter ablation techniques, surgical procedures, and treatment with an implantable atrial defibrillator (IAD). The high prevalence of AF and its clinical complications, the poor efficacy of medical therapy for preventing recurrences, and dissatisfaction with alternative modes of therapy stimulated interest in an IAD [1].
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Lüderitz B, Pfeiffer D, Tebbenjohanns J, Jung W (1996) Nonpharmacologic strategies for treating atrial fibrillation. Am J Cardiol 77: 45A – 52A
Lown B, Amarasingham R, Neuman J (1962) New method for terminating cardiac arrhythmias - use of synchronised capacitor discharge. JAMA 182: 548 – 555
Mower MM, Mirowski M, Denniston RH (1972) Assessment of various models of acetylcholine induced atrial fibrillation for study of intra-atrial cardioversion. Clin Res 20: 388 (abstr)
Dunbar DN, Tobler HG, Fetter J, Gornick CC, Bennson DW, Benditt DG (1986) Intracavitary electrode catheter cardioversion of atrial tachyarrhythmias in the dog. J Am Coll Cardiol 7: 1015 – 1027
Benditt D, Dunbar D, Fetter J, Sakaguchi S, Lurie KG Adler SW (1994) Low-energy transvenous cardioversion defibrillation of atrial tachyarrhythmias in the canine: an assessment of electrode configurations and monophasic pulse sequencing. Am Heart J 127: 994 – 1003
Kumagai K, Yamanouchi Y, Noritami T, Hiroki T, Arakawa K (1990) Low energy synchronous transcatheter cardioversion of atrial flutter/fibrillation in the dog. J Am Coll Cardiol 16: 497 – 501
Powell AC, Garan H, McGovern BA, Fallon JT, Krishnan SC, Ruskin JN (1992) Low energy conversion of atrial fibrillation in the sheep. J Am Coll Cardiol 20: 707 – 711
Cooper RAS, Alferness CA, Smith WM, Ideker RE (1993) Internal cardioversion of atrial fibrillation in sheep. Circulation 87: 1673 – 1686
Tacker WA, Schoenlein WE, Janas W, Ayers GM, Wagner DO (1993) Catheter electrode evaluation for transvenous atrial defibrillation. PACE 16: 853 (abstr)
Ortiz J, Niwano S, Abe H, Gonzalez X, Ayers GM, Waldo AL (1994) Transvenous atrial defibrillation in two canine models of atrial fibrillation. J Am Coll Cardiol 23: 125A (abstr)
Kumagai K, Yamanouchi Y, Hiroki T, Arakwa K (1991) Effect of transcatheter cardioversion on chronic lone atrial fibrillation. PACE 14: 1571 – 1575
Levy S, Lacombe P, Cointe R, Bru P(1988) High energy transcatheter cardioversion of chronic atrial fibrillation. J Am Coll Cardiol 12: 514 – 518
Levy S, Lauribe P, Dolla E, Kou W, Kadish A, Calkins H, Paganelli F, Moyal C, Bremondy M, Schork A, Shyr Y, Das S, Shea M, Gupta N, Morady F (1992) A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 86: 1415 – 1420
Nathan WW, Bexton RS, Spurrell RA, Camm AJ (1984) Internal transvenous low energy cardioversion for the treatment of cardiac arrhythmias. Br Heart J 52: 377 – 384
Keane D, Sulke N, Cooke R, Jackson G, Sowton E (1993) Endocardial cardioversion of atrial flutter and fibrillation. PACE 16: 313 (abstr)
Johnson EE, Yarger MD, Wharton JM (1993) Monophasic and biphasic waveforms for low energy internal cardioversion of atrial fibrillation in humans. Circulation 88: 3184 (abstr)
Murgatroyd FD, Slade AKB, Sopher SM, Rowland E, Ward DE, Camm AJ (1995) Efficacy and tolerability of transvenous low energy cardioversion of paroxysmal atrial fibrillation in humans. J Am Coll Cardiol 25: 1347 – 1353
Alt E, Schmitt C, Ammer R, Coenen M, Fotuhi P, Karch M, Blasini R (1994) Initial experience with intracardiac atrial defibrillation in patients with chronic atrial fibrillation. PACE 17: 1067 – 1078
Kalman JM, Jones EF, Doolan L, Oliver LE, Power JM, Tonkin AM (1995) Low energy endocardial cardioversion of atrial arrhythmias in humans. PACE 18: 1869 – 1875
Jung W, Tebbenjohanns J, Wolpert C, Lüderitz B (1995) Safety, efficacy, and pain perception of internal atrial defibrillation in humans. Circulation 92: 472 (abstr)
Jung W, Pfeiffer D, Wolpert C, Pizzulli L, Fehske W, Schumacher B, Lewalter T, Omran H, Korte T, Lüderitz B (1996) Which patients do benefit from an implantable atrial defibrillator?. J Am Coll Cardiol 27: 301A (abstr)
Schmitt C, Alt E, Plewan A, Ammer R, Leibig M, Karch M, Schömig A (1996) Low energy intracardiac cardioversion after failed conventional external cardioversion of atrial fibrillation. J Am Coll Cardiol 28: 994 – 999
Sopher SM, Murgatroyd FD, Slade AKB, Blankhoff I, Rowland E, Ward DE, Camm AJ (1996) Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks. Heart 75: 635 – 638
Heisel A, Jung J, Fries R, Stopp M, Sen S, Schieffer H, Özbek C (1997) Low energy transvenous cardioversion of short duration atrial tachyarrhythmias in humans using a single lead system. PACE 20: 65 – 71
Levy S, Ricard P, Lau CP, Lok NS, Camm AJ, Murgatroyd FD, Jordaens LJ, Kappenberger LJ, Brugada P, Ripley KL (1997) Multicenter low energy transvenous atrial defibrillation ( XAD) trial results in different subsets of atrial fibrillation. J Am Coll Cardiol 29: 750–755
Ayers GM, Alferness CA, Ilina M, Wagner DO, Sirokman A, Adams JM, Griffin JC (1994) Ventricular proarrhythmic effects of ventricular cycle length and shock strength in a sheep model of transvenous atrial defibrillation. Circulation 89: 413 – 422
Hillsey RE, Wharton M (1995) Implantable atrial defibrillators. J Cardiovasc Electrophysiol 6: 634 – 648
Roelke M, Trouton TG, O’Nunain SS, Garan H, McGovern BA, Ruskin JN (1993) Implantable cardioverter-defibrillator shocks do not convert atrial fibrillation to sinus rhythm. J Am Coll Cardiol 21: 303A (abstr)
Saksena S, Mongeon L, Krol R, Varanasi S, Kolettis T, Mahtew P, DeGroot P, Mehra R (1995) Clinical efficacy and safety of atrial defibrillation using biphasic shocks and current nonthoracotomy endocardial lead configurations Am J Cardiol 76: 913 – 921
Saksena S, Prakash A (1996) Atrial defibrillation: techniques and clinical results. In: Saksena S, Lüderitz B (eds) Interventional electrophysiology. Futura Publishing Co. Inc., Armonk, NY, pp 509 – 520
Poole JE, Kudenchuk PJ, Dolack L, Jones GK, Gleva MJ, Raitt MH, Johnson G, Mehra R, Mongeon L, Bardy GH (1995) Atrial defibrillation using a unipolar single lead right ventricular to pectoral can system. J Am Coll Cardiol 25: 110A (abstr)
Jung W, Mletzko R, Hügl B, Manz M, Lüderitz B (1991) Incidence of atrial tachyarrhythmias following shock delivery of implantable cardioverter/defibrillators. Circulation 84:Ií–612 (abstr)
Jones GK, Johnson G, Troutmann C, Buono G, Gartman DM, Kudenchuk PJ, Polle JE, Dolack GL, Bardy GH (1992) Incidence of atrial fibrillation following ventricular defibrillation with transvenous lead systems in man. J Cardiovasc Electrophysiol 3: 411 – 417
Lau CP, Tse HF, Lok NS, Lee KLF, Ho DSW, Sopher M, Murgatroyd FD, Camm AJ (1997) Initial clinical experience with an implantable human atrial defibrillator. PACE 20: 220 – 225
Levy S, Camm J (1993) An implantable atrial defibrillator. Circulation 87: 1769 – 1772
Levy S, Richard P (1994) Is there any indication for an intracardiac defibrillator for the treatment of atrial fibrillation?. J Cardiovasc Electrophysiol 5: 982 – 985
Touboul P (1995) Atrial defibrillator: Is it needed? Would society pay for it?. PACE 18: 616 – 621
Lau CP, Tse HF, Jung W, Lüderitz B, Sra J,Akhtar M, Sopher M, Camm AJ (1996) Safety and efficacy of a human implantable defibrillator for atrial fibrillation. Circulation 94:I–562 (abstr)
Jung W, Kirchhoff PG, Lau CP, Tse HF, Lüderitz B for the Metrix System Clinical Investigational Group (1997) Therapy delivery with the METRIX automatic atrial defibrillation system: threshold stability and shock safety. J Am Coll Cardiol 29: 78A (abstr)
Jung W, Lüderitz B (1997) Implantation of a new arrhythmia management system in patients with supraventricular and ventricular tachyarrhythmias. Lancet 349: 853 – 854
Lüderitz B, Jung W, Deister A, Manz M (1994) Patient acceptance of implantable cardioverter defibrillator devices: changing attitudes. Am Heart J 127: 1179 – 1184
Jung W, Deister A, Lüderitz B (1997) Quality of life, psychological, and social aspects in patients with implantable cardioverter-defibrillators. In: Allessie M, Fromer M (eds) Atrial and ventricular fibrillation: mechanisms and device therapy. Futura Publishing Co. Inc., Armonk, NY, pp 311 – 320
Lüderitz B, Jung W (1997) Quality of life of patients with atrial fibrillation. In: Santini M (ed) Progress in clinical pacing. Futura Media Sevices Inc., Armonk, NY, pp 253 – 262
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Italia
About this chapter
Cite this chapter
Jung, W., Lüderitz, B. (1998). Implantable Atrial Defibrillator: Which Results and Indications?. In: Raviele, A. (eds) Cardiac Arrhythmias 1997. Springer, Milano. https://doi.org/10.1007/978-88-470-2288-1_14
Download citation
DOI: https://doi.org/10.1007/978-88-470-2288-1_14
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2290-4
Online ISBN: 978-88-470-2288-1
eBook Packages: Springer Book Archive